X

Drug Profile

SB 0110

Alternative Names: SB-0110

Latest Information Update: 23 Jun 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sinopia Biosciences
Class Antiparkinsonians; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

20 Apr 2023 Sinopia Biosciences plans the IND-enabling studies for Parkinson's disease and drug-induced dyskinesia
19 Apr 2023 Preclinical trials in Drug-induced dyskinesia in USA (unspecified route)
19 Apr 2023 Preclinical trials in Parkinson's disease in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com